This study is designed to evaluate the effect of the Shingrix vaccine on the risk of developing dementia, a condition that affects memory, thinking, and reasoning skills. The research focuses on whether receiving this vaccine, which is used to prevent Herpes zoster, also helps in preventing a new diagnosis of this brain-related condition in older adults.
Participants in the study will be assigned to receive either the Shingrix vaccine or a placebo. The Shingrix is a recombinant vaccine, which means it is made using a specific piece of the virus to help the body build protection. The placebo used in this trial is a saline solution, which is a simple mixture of salt and water. The medication will be given as an intramuscular injection, meaning it is delivered directly into the muscle.



Finland